Chinese Biotech Keyi Pharma's BCMA/CD19 Dual-Target CAR-T Therapy KQ-2003 Secures Over $2.1 Billion Global Out-Licensing Deal

On July 22, Novatim announced a strategic partnership with U.S.-based biopharmaceutical company ERIGEN LLC. The two parties signed an exclusive overseas licensing agreement for KQ-2003, Novatim's self-developed, world-first dual-targeting CAR-T cell therapy product with enhanced parallel targeting (targeting BCMA/CD19).

KQ-2003 is an innovative therapy developed by Novatim based on an enhanced dual-target CAR-T platform. Through parallel structural design and signal domain optimization, it significantly enhances the persistence and anti-tumor activity of CAR-T cells while reducing the risk of relapse associated with traditional CAR-T therapies.

According to the PharmaCube database, focusing onBCMA/CD19Dual-target CAR-T Track,NovatimKQ-2003 currently ranks 3rd globally. Additionally, Gracell Biotechnologies, a subsidiary of AstraZeneca, has also developed a similar product.

This collaboration covers global rights outside Greater China (excluding India, Turkey, and Russia), and ERIGEN will obtain exclusive development, registration, and commercialization rights for the product in the relevant regions.In addition, the agreement also grants ERIGEN the right to use the key patent structure and sequence of KQ-2003 for the development of "universal CAR-T cell therapy."

According to the agreement, Novatim retains full rights to this universal product in Greater China, laying the foundation for subsequent co-development and regional commercialization.

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!

Please indicate: Name + Research Direction!

Edition

Authority

Sound

Bright